F18-MHF: Orthopedic Implants-Associated Infection Detection
Launched by EMORY UNIVERSITY · May 25, 2023
Trial Information
Current as of June 27, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new way to detect infections in knee implants using a special imaging technique called PET scanning. The researchers will inject a small amount of a radioactive substance, known as F-18 MHF, into the bloodstream. This will help them see how the substance gathers around knee implants that are either infected or not infected. By comparing the images, they hope to find out if this method can accurately identify infections in patients with knee replacements.
To participate in this trial, you need to be at least 18 years old and able to give written consent. If you have a knee implant and your doctor suspects an infection, especially if you’re scheduled for surgery to address it, you might be eligible. There is also a group for people who have a knee implant without any complications for at least six months. Participants will lie still while undergoing a PET scan for about 90 minutes, and this process will help researchers learn more about detecting knee implant infections effectively.
Gender
ALL
Eligibility criteria
- • Inclusion Criteria for symptomatic patient cohort
- • Patients must be 18 years of age or older, able to provide written informed consent, and ability to lie still for PET scanning.
- • Suspected knee prosthetic infection at least 2 months after original prosthesis placement and who are scheduled to undergo surgery debridement/removal based on the clinical assessment of the referring surgeon.
- • Elevated CRP and ESR
- Exclusion Criteria for symptomatic patient cohort:
- • Undergoing current or recent antimicrobial therapy (within 1 month)
- • Significant comorbidity such as renal failure, septic shock, uncontrolled diabetes
- • Other clinically likely site of infection
- Inclusion Criteria for asymptomatic cohort:
- • Patients must be 18 years of age or older, able to provide written informed consent and ability to lie still for PET scanning
- • Knee prosthesis in situ without complications for 6 months or longer
- Exclusion Criteria for asymptomatic cohort:
- • Clinical or laboratory suspicion of knee prosthesis infection
- • Recent (within 3 months) or current treatment for infected knee prosthesis
- • Significant comorbidity such as renal failure, septic shock, uncontrolled diabetes
About Emory University
Emory University, a leading research institution located in Atlanta, Georgia, is dedicated to advancing medical knowledge and improving patient care through innovative clinical trials. With a strong emphasis on interdisciplinary collaboration, Emory harnesses the expertise of its renowned faculty and state-of-the-art facilities to conduct cutting-edge research across various fields, including oncology, neurology, and infectious diseases. The university's commitment to ethical research practices and patient safety ensures that all clinical trials are designed to generate valuable data that can lead to significant therapeutic advancements. By fostering partnerships with local hospitals and community organizations, Emory strives to translate research findings into real-world applications, ultimately enhancing health outcomes for diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Atlanta, Georgia, United States
Patients applied
Trial Officials
David Schuster, MD
Principal Investigator
Emory University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported